Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data

Bone Marrow Transplantation volume 54, pages 146–149 (2019)Cite this article

Subjects

Access through your institution
Buy or subscribe

Specific anti-cytomegalovirus (CMV) treatment reduces CMV-related mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT), but carries a risk of viral resistance [1]. Treatment failure was defined as the viral load increase > 1 log10 after at least 2 weeks of antiviral therapy [2]. Treatment failure may not be determined only by the biological characteristics of the virus, but also by patient's immunosuppression, drug concentrations in target tissues, etc. [3].

The aim of our study was to determine incidence of treatment failure cases and viral CMV drug resistance in adult HSCT recipients in our center.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–9.

    Article  CAS  Google Scholar 

  2. Ljungman P. ECIL 7 CMV and HHV-6 update group Members.pdf [Internet]. [cited 1 May 2018]. Available from: http://www.ecil-leukaemia.com/telechargements/ECIL%207%20CMV%20final%20slides.pdf

  3. Chevillotte M, von Einem J, Meier BM, Lin F-M, Kestler HA, Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antivir Res. 2010;85:318–27.

    Article  CAS  Google Scholar 

  4. Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol. 2004;74:85–93.

    Article  CAS  Google Scholar 

  5. NCCN Cancer-Related Infections Guideline 2015.pdf [Internet]. [cited 7 Oct 2016]. Available from: http://file.trsgo.org/userfiles/file/NCCN%20Cancer-Related%20Infections%20Guideline%202015.pdf

  6. Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis. 2002;185:162–9.

    Article  CAS  Google Scholar 

  7. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.

    Article  Google Scholar 

  8. Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014;209:557–61.

    Article  Google Scholar 

  9. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes [Internet]. [cited 20 Feb 2017]. Available from: https://www.researchgate.net/publication/12169283_Rising_pp65_antigenemia_during_preemptive_anticytomegalovirus_therapy_after_allogeneic_hematopoietic_stem_cell_transplantation_Risk_factors_correlation_with_DNA_load_and_outcomes

  10. Castor J, Cook L, Corey L, Jerome KR. Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J Clin Microbiol. 2007;45:2681–3.

    Article  CAS  Google Scholar 

  11. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother. 2010;54:2371–8.

    Article  CAS  Google Scholar 

  12. Boutolleau D, Deback C, Bressollette-Bodin C, Varnous S, Dhedin N, Barrou B, et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antivir Res. 2009;81:174–9.

    Article  CAS  Google Scholar 

  13. ECIL 7 CMV final slides.pdf [Internet]. [cited 12 Feb 2018]. Available from: http://www.ecil-leukaemia.com/telechargements/ECIL%207%20CMV%20final%20slides.pdf

  14. Ruutu T. Engraftment EBMT [Internet]. [cited 5 Mar 2017]. Available from: http://www.ebmt.org/Contents/Resources/Library/Slidebank/Documents/EBMT%202011%20SC%20Slide%20Bank/1439%20Ruutu.pdf

Download references

Funding

This research was supported by the program Progress Q40/08 and by The Ministry of Health of the Czech Republic grant MH CZ - DRO (UHHK, 00179906) and by the project for conceptual development of research organization 00064203 of 2nd Medical Faculty of Charles University and Motol University Hospital.

Author information

Authors and Affiliations

  1. 4th Department of Internal Medicine, Haematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

    Eva Vejrazkova, Milan Kostal, Alzbeta Zavrelova, Jakub Radocha & Pavel Zak

  2. Institute of Clinical Biochemistry and Diagnostics, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

    Lenka Pliskova & Radka Kutova

  3. Department of Medical Microbiology of 2nd Medical Faculty, Charles University and Motol University Hospital, Prague, Czech Republic

    Petr Hubacek

  4. Institute of Clinical Microbiology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

    Vlasta Stepanova

Authors
  1. Eva Vejrazkova
    View author publications

    Search author on:PubMed Google Scholar

  2. Lenka Pliskova
    View author publications

    Search author on:PubMed Google Scholar

  3. Petr Hubacek
    View author publications

    Search author on:PubMed Google Scholar

  4. Milan Kostal
    View author publications

    Search author on:PubMed Google Scholar

  5. Alzbeta Zavrelova
    View author publications

    Search author on:PubMed Google Scholar

  6. Jakub Radocha
    View author publications

    Search author on:PubMed Google Scholar

  7. Radka Kutova
    View author publications

    Search author on:PubMed Google Scholar

  8. Vlasta Stepanova
    View author publications

    Search author on:PubMed Google Scholar

  9. Pavel Zak
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Eva Vejrazkova.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vejrazkova, E., Pliskova, L., Hubacek, P. et al. Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data. Bone Marrow Transplant 54, 146–149 (2019). https://doi.org/10.1038/s41409-018-0257-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-018-0257-7

This article is cited by

Search

Advanced search

Quick links